Covid-19 « Science and Enterprise

Light-Activated Treatment Kills Covid-19 Nasal Viruses

By Alan, on January 31st, 2023%

Clinical trial findings show a light-activated disinfectant process kills SARS-CoV-2 viruses in the nose causing Covid-19 infections without harming nasal tissue. . . . → Read More: Light-Activated Treatment Kills Covid-19 Nasal Viruses

CEPI Assessing Advanced RNA Nanoparticle Vaccine

By Alan, on January 12th, 2023%

An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics. . . . → Read More: CEPI Assessing Advanced RNA Nanoparticle Vaccine

Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization

By Alan, on January 3rd, 2023%

Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital. . . . → Read More: Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization

Covid-19 Vaccine Patch Clinical Trial Begins

By Alan, on November 8th, 2022%

Developers of a patch with tiny needles instead of a syringe to deliver vaccines say a clinical trial testing a Covid-19 patch is now underway in Australia. . . . → Read More: Covid-19 Vaccine Patch Clinical Trial Begins

RSV Nose Drops Vaccine Gets FDA Fast Track Tag

By Alan, on November 2nd, 2022%

A vaccine designed from engineered live viruses and taken as nose drops to prevent respiratory syncytial virus received a Food and Drug Administration fast-track designation. . . . → Read More: RSV Nose Drops Vaccine Gets FDA Fast Track Tag

Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised

By Alan, on October 20th, 2022%

A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised

Nasal Spray Vaccines Get CEPI, NIH Funding

By Alan, on October 6th, 2022%

A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea. . . . → Read More: Nasal Spray Vaccines Get CEPI, NIH Funding

Univ. Labs Ink Licensing Deals for Covid-19 Tests

By Alan, on August 5th, 2022%

Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections. . . . → Read More: Univ. Labs Ink Licensing Deals for Covid-19 Tests

Infographic – Fewer in US See Covid-19 Threat

By Alan, on July 30th, 2022%

The percentage of Americans viewing Covid-19 as a major threat to public health is declining, with a majority now saying the disease is a minor or no threat at all. . . . → Read More: Infographic – Fewer in US See Covid-19 Threat

Trial Shows Oral Covid-19 Vaccine Produces Antibodies

By Alan, on July 20th, 2022%

A clinical trial shows a Covid-19 vaccine taken as a tablet produces protective antibodies in nasal membranes that in some cases last for up to a year. . . . → Read More: Trial Shows Oral Covid-19 Vaccine Produces Antibodies

Subscribe for email alerts

Donate to Science & Enterprise

Like us on Facebook

S&E on Mastodon

S&E on LinkedIn

Posts RSS feed

Specials

Guest Posts

Please share Science & Enterprise